Navigation Links
Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations
Date:10/2/2007

aceutical technology from Punjab University and has more than 60 process patents to his credit.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. Where Burnt Out Executives De-stress in Natures Lap
5. Asian Business Executives Urged to Be Eco-friendly
6. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
7. Skin Cancer Research To Go Global
8. Dementia - a global problem
9. Obesity a global problem
10. Suggestions to reduce global heart disease burden
11. Drop in global deaths from measles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider ... content is ICD-10 ready and available to all clients. All Krames Patient Education ... which are more targeted and return a more comprehensive data set of content ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... its partnership with Julia Glushko, professional Tennis player for Israel in the Women’s ... Zensah® Compression for all her training and recovery. , With a focus on ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... -- A new research study conducted by an international team ... including evidence-based guidelines for lower-risk use - to reduce the ... Led by CAMH scientist and CIHR/PHAC* Chair in Applied ... study is being published in the September/October 2011 issue of ...
... of medicines commonly given for pain -- were associated with ... adults, aged 65 to 94, e-published in advance of publication ... The study from researchers at Group Health Research Institute and ... are drugs generally given for insomnia and anxiety, did not ...
... , THURSDAY, Sept. 22 (HealthDay News) -- There ... and other recreational water in the United States in ... to two federal reports released Thursday. The 134 ... and December 2008 occurred in 38 states and Puerto ...
... HealthDay Reporter , THURSDAY, Sept. 22 (HealthDay News) -- ... prostate biopsy are hospitalized within 30 days of the procedure, ... of similarly aged men who do not get prostate biopsies can ... issue of the Journal of Urology . "The overall ...
... By Steven Reinberg HealthDay Reporter , ... containing chloroflouorocarbons (CFCs), which can damage the ozone layer, ... the U.S. Food and Drug Administration announced Thursday. ... Armstrong Pharmaceutical Inc., because it is the only inhaler ...
... of Kentucky,s Dr. Susanne Arnold and colleagues were awarded a ... reasons for the high lung cancer rates in Eastern Kentucky. ... the study began on Sept. 15. Kentucky has the ... the southeastern portion of the state those in the ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
(Date:8/27/2015)... Aug. 27, 2015  QB3@953—a San ... University of California (UC) research institute and biotech ... GSK to identify and facilitate collaborations to translate ... patients. The agreement formalizes a relationship ... (DPAc) team and creates a new channel for ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... Chief Executive Officer, will present a corporate overview and business ... New York City . , 22 ... 11:30 am ET at the Millennium Broadway Hotel. , ... pm ET at the St. Regis Hotel. To ...
(Date:8/26/2015)... , Aug. 26, 2015 The North ... witness a CAGR of 7.8% during the forecast period, ... ophthalmology cataract surgery devices market in 2014 and accounted ... ophthalmology cataract surgery devices market is expected to witness ... the increasing strategic expansion of the companies and continuous ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2SciClone To Present At Two Investor Conferences On September 10, 2015 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 14 Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer ... announced it has received FDA 510(k) clearance for the new ... Fraxel re:store Dual system takes the industry leading ... 1927 nm wavelength, the first ever application of a Thulium laser ...
... 14 Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... tender offer for a portion of its outstanding 2.875% Senior ... "Modified Dutch Auction" procedure, Par is offering to purchase, for ... up to approximately 82.7%, of the outstanding convertible notes, at ...
Cached Medicine Technology:Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 2Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 2Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 4
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: